Dudum Andrew's Form 4/A amendment
AmendedHims & Hers Health, Inc. (HIMS) · filed Jan 23, 2025
- Accession no.
- 0001773751-25-000014
- Filed
- Jan 23, 2025
- Trade date
- Jan 16, 2025
- Filing delay
- 7 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Jan 21, 2025
This filing lists 2 derivative transactions. It carries over 7 transactions from the original filing that it did not restate. Open-market sales total $2.27M. It was filed 7 days after the trade.
This amendment restates part of 0001773751-25-000012 (filed Jan 21, 2025). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dudum AndrewCIK 0001837796 | Director, Officer (Chief Executive Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 16, 2025 | Class A Common Stock | MOption exerciseDisposed | −17,001 | $0.00 | $0 | 170,014 | Direct | |
| Jan 16, 2025 | Class A Common Stock | MOption exerciseDisposed | −16,667 | $0.00 | $0 | 1,548,068 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001773751-25-000012 (filed Jan 21, 2025).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 16, 2025 | Class A Common Stock | MOption exerciseAcquired | +33,668 | $2.43 | +$81,813.24 | 64,378 | Direct | |
| Jan 16, 2025 | Class A Common Stock | SSaleDisposed | −25,915 | $27.03F2 | −$700,482.45 | 38,463 | Direct | |
| Jan 16, 2025 | Class A Common Stock | SSaleDisposed | −7,753 | $27.22F3 | −$211,036.66 | 30,710 | Direct | |
| Jan 16, 2025 | Class A Common Stock | SSaleDisposed | −1,692 | $27.04F4 | −$45,751.68 | 29,018 | Direct | |
| Jan 16, 2025 | Class A Common Stock | SSaleDisposed | −1,100 | $27.40F3 | −$30,140 | 27,918 | Direct | |
| Jan 16, 2025 | Class A Common Stock | SSaleDisposed | −40,553 | $26.96F5 | −$1,093,308.88 | 482,311 | Indirect | |
| Jan 16, 2025 | Class A Common Stock | SSaleDisposed | −6,981 | $27.28F6 | −$190,441.68 | 475,330 | Indirect |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F2
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $26.70 - $27.115. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $27.12 - $28.105. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 2 transactions in Table I.
- F4
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $27.01 - $27.085. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $26.72 - $27.12. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F6
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $27.125 - $28.105. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The form is being revised to show the correct option award being used for this transaction.
- F2
The stock option exercises reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.
- F3
Prior to the Company's business combination transaction in 2021, the option represented the right to purchase 7,166,182 shares of Hims, Inc. with an exercise price of $1.10. Following the Company's business combination transaction in 2021, the option converted into the right to purchase 3,246,139 shares of the Company with an exercise price of $2.43. 100% of the shares subject to the option vested upon certain specified thresholds met in 2021.
- F4
The Stock Option was received in exchange for an option to purchase 3,583,091 shares of Class A Common Stock of Hims, Inc., with an exercise price of $1.10, in connection with the Merger. 1/48 of the shares subject to the Stock Option vest when the Reporting Person completes each month of continuous Service beginning March 13, 2020.